Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus

Byram W. Bridle; Jeanette E. Boudreau; Brian D. Lichty; Jérôme Brunellière; Kyle Stephenson; Sandeep Koshy; Jonathan L. Bramson; Yonghong Wan

doi:10.1038/mt.2009.154

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus

Byram W. Bridle, Jeanette E. Boudreau, Brian D. Lichty, Jérôme Brunellière, Kyle Stephenson, Sandeep Koshy, Jonathan L. Bramson, Yonghong Wan

Résultat de recherche: Article › examen par les pairs

97 Citations (Scopus)

Résumé

Vesicular stomatitis virus (VSV) has proven to be an effective vaccine vector for immunization against viral infection, but its potential to induce an immune response to a self-tumor antigen has not been investigated. We constructed a recombinant VSV expressing human dopachrome tautomerase (hDCT) and evaluated its immunogenicity in a murine melanoma model. Intranasal delivery of VSV-hDCT activated both CD4⁺ and CD8⁺ DCT-specific T-cell responses. The magnitude of these responses could be significantly increased by booster immunization with recombinant adenovirus (Ad)-hDCT, which led to enhanced efficacy against B16-F10 melanoma in both prophylactic and therapeutic settings. Notably, the interval of VSV/Ad heterologous vaccination could be shortened to as few as 4 days, making it a potential regimen to rapidly expand antigen-specific effector cells. Furthermore, VSV-hDCT could increase DCT-specific T-cell responses primed by Ad-hDCT, suggesting VSV is efficient for both priming and boosting of the immune response against a self-tumor antigen.

Langue d'origine	English
Pages (de-à)	1814-1821
Nombre de pages	8
Journal	Molecular Therapy
Volume	17
Numéro de publication	10
DOI	https://doi.org/10.1038/mt.2009.154
Statut de publication	Published - 2009
Publié à l'externe	Oui

Note bibliographique

Funding Information:
We thank Mary-Jo Smith and Mary Bruni for assistance with immunohistochemical staining; Xueya Feng, Duncan Chong, and Natasha Kazdhan for technical assistance with virus preparation. This work was supported by grants to Y.W. from the Canadian Institutes of Health Research [MOP-67066] and the Ontario Cancer Research Network. J.E.B. is supported by studentships from the Natural Sciences and Engineering Research Council. We have no financial conflicts of interest related to this research.

ASJC Scopus Subject Areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1038/mt.2009.154

Autres fichiers et liens

Citer

@article{7ab8e7c76e784e39a177a124c4ee7ca4,

title = "Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus",

abstract = "Vesicular stomatitis virus (VSV) has proven to be an effective vaccine vector for immunization against viral infection, but its potential to induce an immune response to a self-tumor antigen has not been investigated. We constructed a recombinant VSV expressing human dopachrome tautomerase (hDCT) and evaluated its immunogenicity in a murine melanoma model. Intranasal delivery of VSV-hDCT activated both CD4+ and CD8+ DCT-specific T-cell responses. The magnitude of these responses could be significantly increased by booster immunization with recombinant adenovirus (Ad)-hDCT, which led to enhanced efficacy against B16-F10 melanoma in both prophylactic and therapeutic settings. Notably, the interval of VSV/Ad heterologous vaccination could be shortened to as few as 4 days, making it a potential regimen to rapidly expand antigen-specific effector cells. Furthermore, VSV-hDCT could increase DCT-specific T-cell responses primed by Ad-hDCT, suggesting VSV is efficient for both priming and boosting of the immune response against a self-tumor antigen.",

author = "Bridle, {Byram W.} and Boudreau, {Jeanette E.} and Lichty, {Brian D.} and J{\'e}r{\^o}me Brunelli{\`e}re and Kyle Stephenson and Sandeep Koshy and Bramson, {Jonathan L.} and Yonghong Wan",

note = "Funding Information: We thank Mary-Jo Smith and Mary Bruni for assistance with immunohistochemical staining; Xueya Feng, Duncan Chong, and Natasha Kazdhan for technical assistance with virus preparation. This work was supported by grants to Y.W. from the Canadian Institutes of Health Research [MOP-67066] and the Ontario Cancer Research Network. J.E.B. is supported by studentships from the Natural Sciences and Engineering Research Council. We have no financial conflicts of interest related to this research.",

year = "2009",

doi = "10.1038/mt.2009.154",

language = "English",

volume = "17",

pages = "1814--1821",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus

AU - Bridle, Byram W.

AU - Boudreau, Jeanette E.

AU - Lichty, Brian D.

AU - Brunellière, Jérôme

AU - Stephenson, Kyle

AU - Koshy, Sandeep

AU - Bramson, Jonathan L.

AU - Wan, Yonghong

N1 - Funding Information: We thank Mary-Jo Smith and Mary Bruni for assistance with immunohistochemical staining; Xueya Feng, Duncan Chong, and Natasha Kazdhan for technical assistance with virus preparation. This work was supported by grants to Y.W. from the Canadian Institutes of Health Research [MOP-67066] and the Ontario Cancer Research Network. J.E.B. is supported by studentships from the Natural Sciences and Engineering Research Council. We have no financial conflicts of interest related to this research.

PY - 2009

Y1 - 2009

N2 - Vesicular stomatitis virus (VSV) has proven to be an effective vaccine vector for immunization against viral infection, but its potential to induce an immune response to a self-tumor antigen has not been investigated. We constructed a recombinant VSV expressing human dopachrome tautomerase (hDCT) and evaluated its immunogenicity in a murine melanoma model. Intranasal delivery of VSV-hDCT activated both CD4+ and CD8+ DCT-specific T-cell responses. The magnitude of these responses could be significantly increased by booster immunization with recombinant adenovirus (Ad)-hDCT, which led to enhanced efficacy against B16-F10 melanoma in both prophylactic and therapeutic settings. Notably, the interval of VSV/Ad heterologous vaccination could be shortened to as few as 4 days, making it a potential regimen to rapidly expand antigen-specific effector cells. Furthermore, VSV-hDCT could increase DCT-specific T-cell responses primed by Ad-hDCT, suggesting VSV is efficient for both priming and boosting of the immune response against a self-tumor antigen.

AB - Vesicular stomatitis virus (VSV) has proven to be an effective vaccine vector for immunization against viral infection, but its potential to induce an immune response to a self-tumor antigen has not been investigated. We constructed a recombinant VSV expressing human dopachrome tautomerase (hDCT) and evaluated its immunogenicity in a murine melanoma model. Intranasal delivery of VSV-hDCT activated both CD4+ and CD8+ DCT-specific T-cell responses. The magnitude of these responses could be significantly increased by booster immunization with recombinant adenovirus (Ad)-hDCT, which led to enhanced efficacy against B16-F10 melanoma in both prophylactic and therapeutic settings. Notably, the interval of VSV/Ad heterologous vaccination could be shortened to as few as 4 days, making it a potential regimen to rapidly expand antigen-specific effector cells. Furthermore, VSV-hDCT could increase DCT-specific T-cell responses primed by Ad-hDCT, suggesting VSV is efficient for both priming and boosting of the immune response against a self-tumor antigen.

UR - http://www.scopus.com/inward/record.url?scp=70349864985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349864985&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.154

DO - 10.1038/mt.2009.154

M3 - Article

C2 - 19603003

AN - SCOPUS:70349864985

SN - 1525-0016

VL - 17

SP - 1814

EP - 1821

JO - Molecular Therapy

JF - Molecular Therapy

IS - 10

ER -

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer